Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy of Treatment Sequences in Patients With ALK and ROS-1 Positive Non-small Cell Lung Cancer Who Received Lorlatinib as Part of the French Expanded Access Program

NCT03727477 is registered in ClinicalTrials.gov with Intergroupe Francophone de Cancerologie Thoracique as lead sponsor.

NCT NCT03727477
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03727477 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy of Treatment Sequences in Patients With ALK and ROS-1 Positive Non-small Cell Lung Cancer Who Received Lorlatinib as Part of the French Expanded Access Program
Lead sponsor
Intergroupe Francophone de Cancerologie Thoracique
Phase
Observational
Overall status
Completed
Start date
February 1, 2019
Completion date
October 12, 2020
Enrollment
291 (actual)
Sites
30

Conditions

As the registry lists them; a condition with its own page is linked.

alk gene rearrangement positive, non-small cell lung cancer metastatic, ros-1 gene rearrangement positive